Cells have evolved a complex network of biochemical pathways, collectively known as the
DNA damage response (DDR), to prevent detrimental mutations from being passed on to …

Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …

Background In a phase 2 study, rucaparib, an inhibitor of poly (ADP-ribose) polymerase
(PARP), showed a high level of activity in patients who had metastatic, castration-resistant …

PURPOSE Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal
disease with current standard-of-care therapies. Homologous recombination repair (HRR) …

Background Metastatic castration-resistant prostate cancer remains fatal despite recent
advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic …

Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant
prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of …

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a
prostate cancer diagnosis and include management options for localized, regional, and …

Background Metastatic castration-resistant prostate cancers are enriched for DNA repair
gene defects (DRDs) that can be susceptible to synthetic lethality through inhibition of PARP …

Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

Simple Summary DNA damage is one of the hallmarks of cancer. Epithelial ovarian cancer
(EOC)—especially the high-grade serous subtype—harbors a defect in at least one DNA …